🚀 Pharmidex at BioWednesday Stevenage 🚀
February 5, 2025
We are excited to share that our Business Development Manager, Janette Dalay Robertson, and Head of Operations,
Ash Alavijeh, had the pleasure of attending the BioWednesday Stevenage: Key Messages and Sentiments from JPM Week 2025 event today at the
Stevenage Bioscience Catalyst.
It was a fantastic opportunity to connect with industry leaders, potential clients, and partners. Janette and Ash were thrilled to engage in meaningful conversations, exploring new collaborations, and discussing the latest insights from JPM Week 2025.
At Pharmidex, we're committed to expanding our relationships and helping our clients navigate their path to success in drug discovery and development. Together, we’re working towards creating a healthier future.
A big thank you to everyone we had the pleasure of meeting today. We look forward to the continued conversations and collaborations!
#Pharmidex #BioWednesday #JPMWeek2025 #DrugDiscovery #Biotech #Innovation #Pharmaceuticals #Networking #StevenageBioScienceCatalyst
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩🔬 👨🔬 Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs. ✅ Human-relevant metabolism data ✅ Supports IND-enabling ®gulatory studies ✅ Ideal for metabolite profiling, DDI risk & toxicity assessment By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development. 📩 Contact us to see how 8HUM can support your project.
